Did You Know?

Editor’s Picks

Latest News

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with...

LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress

NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines...

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

Furoscix ReadyFlow™ Furoscix ReadyFlow™ Furoscix ReadyFlow™ Furoscix ReadyFlow™ New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated...

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

error: Content is protected !!